Malignant Pleural Mesothelioma Nodal Status: Where Are We at?
| Autor: | Ricciardi S; Unity of Thoracic Surgery, Hospital of Bologna, IRCCS University, 40138 Bologna, Italy.; Alma Mater, Studiorum University of Bologna, 40138 Bologna, Italy., Carleo F; Unity of Thoracic Surgery, San Camillo Forlanini Hospital, 00152 Rome, Italy., Jaus MO; Unity of Thoracic Surgery, San Camillo Forlanini Hospital, 00152 Rome, Italy., Di Martino M; Unity of Thoracic Surgery, San Camillo Forlanini Hospital, 00152 Rome, Italy., Carbone L; Unity of Thoracic Surgery, San Camillo Forlanini Hospital, 00152 Rome, Italy., Ricci A; Respiratory Unit, Sant'Andrea Hospital, 00189 Rome, Italy.; Medicina Clinica e Molecolare, University of Rome La Sapienza, 00185 Rome, Italy., Cardillo G; Unity of Thoracic Surgery, San Camillo Forlanini Hospital, 00152 Rome, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical medicine [J Clin Med] 2021 Nov 05; Vol. 10 (21). Date of Electronic Publication: 2021 Nov 05. |
| DOI: | 10.3390/jcm10215177 |
| Abstrakt: | Due to the lack of both prospective trial and high-volume retrospective studies, the management of clinical N+ malignant pleural mesothelioma (MPM) patients remains highly debated. Node positive patients show poor survival compared with node-negative ones; thus, lymph node staging appears crucial in determining treatment strategy. Notwithstanding the improvement in pre-treatment staging and the update on lymph node classification in the 8th edition of TNM, several open controversies remain on N parameter. How should we stage suspected N+ patients? How should we treat node positive patients? Which is the definition of a "resectable patient"? Is the site or the number the main prognostic factor for node positive patients? The aim of our narrative review is to analyse the existing relevant literature on lymph node status in MPM. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|